-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Decitabine + Tetrahydrouridine) in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Decitabine + Tetrahydrouridine) in Sickle Cell Disease Drug Details: Decitabine in combination with tetrahydrouridine is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYL-845 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Metastatic Melanoma Drug Details: LYL-845 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-132 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYL-132 in Non-Small Cell Lung Cancer Drug Details: LYL-132 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma Drug Details: TJC-4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Solid Tumor Drug Details: LYL-845 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Non-Small Cell Lung Cancer Drug Details: LYL-845 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Metastatic Colorectal Cancer Drug Details: LYL-845 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PTC-589 in Parkinson’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PTC-589 in Parkinson's Disease Drug Details: EPI-589 (BioE-589) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masofaniten in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masofaniten in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masofaniten in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Masofaniten...